# Study of Pembrolizumab (MK-3475) vs. Brentuximab Vedotin in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma (MK-3475-204/KEYNOTE-204)

> **NCT02684292** · PHASE3 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 304 (actual)

## Conditions studied

- Hodgkin Lymphoma

## Interventions

- **BIOLOGICAL:** pembrolizumab
- **BIOLOGICAL:** brentuximab vedotin

## Key facts

- **NCT ID:** NCT02684292
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-05-23
- **Primary completion:** 2026-01-14
- **Final completion:** 2026-01-14
- **Target enrollment:** 304 (ACTUAL)
- **Last updated:** 2026-02-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02684292

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02684292, "Study of Pembrolizumab (MK-3475) vs. Brentuximab Vedotin in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma (MK-3475-204/KEYNOTE-204)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02684292. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*